valuation thoughts, page-304

So does CHM know if a safe dose was established?

In layman's terms, the hoped end result of the Core-NK platform is 3rd gen. To get there we will have to work through 2nd and then 3rd gen treatments, at each stage combining researched therapies to create this proposed CORE-NK 3rd gen super-killer of cancer cells.

Will we have to go through 3 phase trial in each case?

ORwill we be able to market each generation?

IF the phase 2 trial of our 1st generation CORE-NK is registrational, will CHM market this as a treatment and use the commercial proceeds to work through 2nd and 3rd gen, at each stage hopefully making a new drug?

Surely CHM would not wait until 3rd gen/phase 2 or 3 if we get some kind of efficacious treatments at earlier generations / phases?

Thanks for answering my questions, you seem to understand what you are talking about.